Skip to main content

The plant sterol brassicasterol as additional CSF biomarker in Alzheimer’s disease

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Vanmierlo T, Popp J, Kölsch H, Friedrichs S, Jessen F, Stoffel‐Wagner B, Bertsch T, Hartmann T, Maier W, von Bergmann K, Steinbusch H, Mulder M, Lütjohann D. The plant sterol brassicasterol as additional CSF biomarker in Alzheimer’s disease.

Objective:  Plant sterols (sitosterol, campesterol, stigmasterol and brassicasterol) are solely dietary‐derivable sterols that are structurally very similar to cholesterol. In contrast to peripheral cholesterol, plant sterols can cross the blood–brain barrier and accumulate within mammalian brain. As an impaired function of the cerebrospinal fluid (CSF)–blood barrier is linked to neurodegenerative disorders, i.e. Alzheimer’s disease (AD), we investigated whether this results in altered plant sterol concentrations in CSF.

Method:  Applying gas chromatography/mass spectrometry analysis, plant sterol concentrations were measured in plasma and CSF of patients with AD (n = 67) and controls (n = 29). Age, gender, plasma‐to‐CSF albumin ratio, CSF Aβ42, CSF pTau, APOE4 genotype, and serum creatinine were applied as covariates in the statistical analysis for individual plant sterols in order to compare plasma and CSF plant sterol concentrations between patients with AD and controls.

Results:  Albumin quotient was a consistent predictor in CSF for cholesterol and methyl plant sterols campesterol and brassicasterol. Comparison of lipid parameters per diagnosis based on relevant predictors revealed significantly lower concentrations of brassicasterol (P < 0.001) in CSF of patients with AD. Binary logistic regression analysis revealed that brassicasterol improved the predictive value when added to pTau and Aβ42 in a biomarker model.

Conclusion:  Brassicasterol might be a relevant additional biomarker in AD.

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1600-0447.2011.01713.x

Affiliations: 1: Department of Psychiatry, University of Bonn, Bonn, Germany 2: Institute of Clinical Chemistry and Clinical Pharmacology, University Clinics Bonn, Bonn, Germany 3: Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Nuremberg Clinic, Nuremberg, Germany 4: German Institute for Dementia Prevention, Neurodegeneration and Neurobiology, Saarland University, Homburg/Saar, Germany 5: Department of Internal Medicine, Division of Pharmacology, Vascular and Metabolic Diseases, Erasmus Medical Center, Rotterdam, the Netherlands

Publication date: September 1, 2011

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more